Piper Sandler raised the firm’s price target on Biohaven to $66 from $36 and keeps an Overweight rating on the shares after layering BHV-1300 — the company’s novel IgG degrader — into its model. The firm anticipates positive FIH data this quarter and a proposed commercial roll-out with a partner starting in 2029. Piper remains a buyer of the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHVN: